Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Sanofi India Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended September 30, 2016
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here Sanofi awaits govt approval to launch dengue vaccine in India
After receiving authorization in 11 countries, Sanofi Pasteur is still awaiting for approval from the government to launch its dengue vaccine Dengvaxia in India. Sanofi gets $43 million U.S. funding to spur Zika vaccine development
The funding from the Biomedical Advanced Research and Development Authority (BARDA) will be used for mid-stage trials, expected to begin in the first half of 2018.
Alphabet, Sanofi to invest $500 million in diabetes joint venture
Sanofi expects increased competition in the diabetes market to remain as cheaper copies of biotech drugs known as biosimilars are rolled out Investors stay positive as corporate yields turn negative
French pharmaceuticals company Sanofi sold a 1bn long three-year and German consumer goods producer Henkel a 500m two-year - both at a -0.05% yield. Don't bring a drug under price control because it's widely sold: Shailesh Ayyangar
Interview with Sanofi India managing director Updates on Outcome of AGM
Sanofi India Ltd has submitted to BSE a copy of Minutes of the proceedings of the 60th Annual General Meeting (AGM) of the Company held on April 29, 2016. Sanofi cross-border deal: SC refuses to give early hearing:
The Supreme Court on Monday refused to grant early hearing in the Rs1,058-crore Sanofi SA cross-border deal involving Indian assets of Hyderabad-based Shantha Biotechnics (SBL). The post Sanofi cross-border deal: SC refuses to give earlyhearing: appeared first on The Financial Express.
Sanofi India Q2 profit rises 33% to Rs85 crore
Standalone total income from operations of Sanofi India rose to Rs608 crore in June quarter as against Rs549.7 crore in the year-ago period